Heart Failure

The AJMC® Heart Failure compendium is a comprehensive resource for clinical news and expert insights for the chronic condition in which the heart doesn't pump enough blood due to damaged heart muscle.

Latest News

AJMC
Temporal Shift in Prevalence of Heart Failure Diagnoses and Comorbidities Within 2 US Integrated Health Systems

August 14th 2025

The analysis highlighted a shift in heart failure diagnoses, with hypertensive heart disease with and without chronic kidney disease as prevalent diagnoses, underlining coding variability and implications for research.

A new clinical drug trial tests the efficacy and safety of finerenone, used to help reduce potassium expulsion for people on diuretics. | Image Credit: AdobeStock_ PhotobyTawat.jpeg
Finerenone Demonstrates Safety and Efficacy in Heart Failure When Combined With Diuretics

August 13th 2025

Genetic factors may increase the risk of developing dilated cardiomyopathy in addition to covariates like age and sex. | Image Credit: AdobeStock_jaojormami.jpeg
Genetics, Comorbidities Associated With Cardiomyopathy and Atrial Fibrillation

August 13th 2025

Left bundle branch block may be an significant indicator of heart failure succeeding previous risk-factors like diabetes and hypertension. | Image Credit: AdobeStock_phonlamaiphoto.jpeg
Left Bundle Branch Block May Be Key Indicator of Progressive Heart Failure

August 8th 2025

Researchers measured physical activity trajectories before and after CVD events like coronary heart disease, stroke, and heart failure. | Image Credit: LIGHTFIELDSTUDIOS - stock.adobe.com
Strategies Needed to Address Physical Activity Before, After CVD Events

August 1st 2025

Continuing Medical Education
View All
August 21st 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 21st 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology
August 21st 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
August 21st 2025

Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative

1.5 Credits / Cardiology
August 21st 2025

The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

1.5 Credits / Cardiology, Rare Diseases
August 21st 2025

Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

1.5 Credits / Pulmonology, Cardiology, Rare Diseases

More News

Trial Data Suggest Beta Blockers Not Best Choice in Heart Failure With Preserved Ejection Fraction
December 13th 2019

Trial Data Suggest Beta Blockers Not Best Choice in Heart Failure With Preserved Ejection Fraction

Mary Caffrey
The results are sure to generate interest as heart failure with preserved ejection fraction lacks treatment options, but that could change as results are expected in outcomes trials that are studying sodium glucose co-transporter 2 inhibitors in heart failure, both with preserved and reduced ejection fraction.
Dr John McMurray Details the Preliminary Cost-Effectiveness Distinction of Dapagliflozin
December 7th 2019

Dr John McMurray Details the Preliminary Cost-Effectiveness Distinction of Dapagliflozin

Cost-effectiveness analyses have not been conducted on the DAPA-HF trial as of yet, but in healthcare systems in which dapagliflozin is not particularly expensive, results are likely to be favorable, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
Want a Low-Cost Way to Prevent Heart Failure? Brush Your Teeth, Study Suggests
December 3rd 2019

Want a Low-Cost Way to Prevent Heart Failure? Brush Your Teeth, Study Suggests

Mary Caffrey
Although the study did not pinpoint the exact mechanism behind the link, the authors wrote that the presence of plaque below the gumline can allow oral bacteria to reach the circulatory system. Certain bacteria that reach the gut can trigger inflammation.
Dr John McMurray: Dapagliflozin Excels as a Preventive and Established Treatment for Heart Failure
November 30th 2019

Dr John McMurray: Dapagliflozin Excels as a Preventive and Established Treatment for Heart Failure

Dapagliflozin was shown to not only benefit patients at risk of heart failure, both with and without diabetes, but treat patients with established heart failure as well, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
Number of Cardiovascular Deaths Rising Among Cancer Survivors, Study Finds
November 26th 2019

Number of Cardiovascular Deaths Rising Among Cancer Survivors, Study Finds

Mary Caffrey
A new study says that more than 1 in 10 of the 17 million cancer survivors in the United States will die from cardiovascular disease (CVD).
Dr John McMurray Explains the Heart Failure Benefits of Dapagliflozin in Patients With and Without Diabetes
November 23rd 2019

Dr John McMurray Explains the Heart Failure Benefits of Dapagliflozin in Patients With and Without Diabetes

In patients with heart failure, both with and without diabetes, dapagliflozin was shown to provide identical efficacy and possibly beneficial effects on the heart, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
This Week in Managed Care: November 22, 2019
November 22nd 2019

This Week in Managed Care: November 22, 2019

This week, the top managed care news included research that shows stents may offer no more value than drugs for some heart patients; a ban on flavored tobacco products gains momentum; a survey finds most American families struggle with social factors that impact health.
Neurohormonal Blockade, Left Ventricular Assist Devices Equal Improved Survival Outcomes in Patients With Heart Failure
November 22nd 2019

Neurohormonal Blockade, Left Ventricular Assist Devices Equal Improved Survival Outcomes in Patients With Heart Failure

Maggie L. Shaw
Quality of life and 6-minute walk test also improve with this treatment combination.
AstraZeneca Initiative to Highlight Link Between Diabetes, Heart Failure
November 15th 2019

AstraZeneca Initiative to Highlight Link Between Diabetes, Heart Failure

Mary Caffrey
Called Diabetes Can Break Your Heart, the initiative seeks to get doctors and patients talking about the connection between diabetes and heart failure, so that symptoms are not missed and treatment that could prevent heart failure occurs early. A Diabetes Heartbreaker tour, which will feature a virtual reality experience with immersive technology, will kick off this weekend at the American Heart Association Scientific Sessions in Philadelphia.
Mavacamten Has Positive Impact on Cardiac Structure in Certain Cases of Cardiomyopathy, Data Show
November 11th 2019

Mavacamten Has Positive Impact on Cardiac Structure in Certain Cases of Cardiomyopathy, Data Show

Mary Caffrey
Hypertrophic cardiomyopathy is often an inherited condition and patients may not show symptoms, or those symptoms may be vague, such as fatigue or shortness of breath. The condition can cause varied levels of risk and can result in sudden cardiac death.
Kaiser Permanente Study Results Suggest Link Between Older Age, Heart Failure
November 6th 2019

Kaiser Permanente Study Results Suggest Link Between Older Age, Heart Failure

Maggie L. Shaw
The rate of decrease in deaths from heart disease (HD) slowed between 2011 and 2014 versus 2000 and 2011, while the population above 65 years jumped 22.9% and there was a concurrent 38% rise in deaths from HD among this patient population.
Researchers Find Possible Treatment Target for Heart Failure
November 4th 2019

Researchers Find Possible Treatment Target for Heart Failure

Mary Caffrey
Researchers at the University of Alabama at Birmingham first isolated the kinase HIPK2 from among hundreds of potential targets by using bioinformatics to hone in on the protein kinase as a target for study.
What We're Reading: Number of Uninsured Children Soars; Heart Failure Deaths Rise; Alabama Abortion Ban Halted
October 30th 2019

What We're Reading: Number of Uninsured Children Soars; Heart Failure Deaths Rise; Alabama Abortion Ban Halted

AJMC Staff
The number of uninsured children in the United States rose by more than 400,000 between 2016 and 2018 and now stands at over 4 million; mortality from heart failure rose 20.7% between 2011 and 2017 and is likely to keep climbing sharply; US District Judge Myron Thompson issued a preliminary injunction temporarily blocking Alabama from enforcing a near-total abortion ban.
FDA Approves Dapagliflozin to Cut Risk of Hospitalization for Heart Failure in Type 2 Diabetes
October 21st 2019

FDA Approves Dapagliflozin to Cut Risk of Hospitalization for Heart Failure in Type 2 Diabetes

Mary Caffrey
Results are based on the DECLARE-TIMI 58 cardiovascular outcomes trial, presented last year at the American Heart Association Scientific Sessions.
FDA Approves Canagliflozin to Prevent Kidney Failure, Hospitalization for Heart Failure
October 1st 2019

FDA Approves Canagliflozin to Prevent Kidney Failure, Hospitalization for Heart Failure

Mary Caffrey
The new indication is based on results of the CREDENCE trial, which found that canagliflozin reduced the risk of renal failure or death by 30% in those that had both type 2 diabetes and diabetic kidney disease.
This Week in Managed Care: September 20, 2019
September 20th 2019

This Week in Managed Care: September 20, 2019

This week, the top managed care stories included Purdue Pharma filing for bankruptcy; new data showing the number of people who get screened for HIV at least once falls far short of what CDC recommends; findings that most US hospital markets are now highly concentrated.
What We're Reading: Fast Track Designation for Dapagliflozin; California Advocates Against Vaping; Measles Cases Fading
September 17th 2019

What We're Reading: Fast Track Designation for Dapagliflozin; California Advocates Against Vaping; Measles Cases Fading

AJMC Staff
The FDA grants fast track designation of AstraZeneca's dapagliflozin; California to conduct public awareness campaign against vaping; no new US measles cases.
This Week in Managed Care: September 6, 2019
September 6th 2019

This Week in Managed Care: September 6, 2019

This week, the top managed care news included a diabetes drug showing positive results in treating heart failure; new lipid guidelines promoting the use of proprotein convertase subtilisin/kexin type 9 inhibitors; and a study finding doctors are more likely to prescribe opioids if they are in a hurry.
5 Things to Look for at the European Society of Cardiology 2019 Congress
August 23rd 2019

5 Things to Look for at the European Society of Cardiology 2019 Congress

Mary Caffrey
Studies on anticoagulants and SGLT2 inhibitors, and guidelines for dyslipidemia and more are anticipated at the meeting.
This Week in Managed Care: August 23, 2019
August 23rd 2019

This Week in Managed Care: August 23, 2019

This week in managed care, the top news included outcomes results in treating heart failure; US prevention experts said more women should get BRCA testing; the American Heart Association offered an advisory on treating high triglycerides with prescription omega-3 fatty acids.
AstraZeneca's Dapagliflozin Meets Primary End Point in Heart Failure Trial
August 20th 2019

AstraZeneca's Dapagliflozin Meets Primary End Point in Heart Failure Trial

Mary Caffrey
Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure includes patients with and without type 2 diabetes, although the topline results did not specify if results were similar in these 2 populations.
Site Logo
June 29th 2019

AstraZeneca's Khan Discusses Dapagliflozin and Cardiovascular, Renal Outcomes in Diabetes Care

Mary Caffrey
A discussion with Naeem Khan, MD, vice president of US cardiovascular and metabolic diseases at AstraZeneca, on lessons from the wave of cardiovascular outcomes trials, the new focus on renal outcomes, and what’s next for SGLT2 inhibitors.
FDA's Fast Track Designation for Empagliflozin in Heart Failure Points to New Paradigm
June 28th 2019

FDA's Fast Track Designation for Empagliflozin in Heart Failure Points to New Paradigm

Mary Caffrey
The EMPEROR trials could lead to new indications for the SGLT2 inhibitor for patients with and without diabetes.
This Week in Managed Care: May 10, 2019
May 10th 2019

This Week in Managed Care: May 10, 2019

This week, the top managed care news included HHS announcing a finalized rule requiring the disclosure of drug prices in television ads; a report finding high satisfaction with employer health coverage despite the cost; a study finding heart failure is surging among young adults.
What We're Reading: Medicaid Fraud Settlement; Heart Failure in Young Adults; FDA Investigates Sunscreen
May 7th 2019

What We're Reading: Medicaid Fraud Settlement; Heart Failure in Young Adults; FDA Investigates Sunscreen

AJMC Staff
Federal prosecutors have reached a $17 million settlement with Acadia after Medicaid fraud allegations; rates of heart failure–related deaths are on the rise among adults between 35 and 64 years old; the FDA has asked manufacturers of sunscreen to review the safety of the chemicals used in their products after a new study found that many of the ingredients in sunscreen may be absorbed into the bloodstream upon use.
5 Takeaways From the 2019 American College of Cardiology Meeting
March 22nd 2019

5 Takeaways From the 2019 American College of Cardiology Meeting

Mary Caffrey
For SGLT2 inhibitors and a fish oil capsule, there was plenty of good news; for aspirin, not so much. A recap of the American College of Cardiology's 68th Annual Scientific Session, held March 16-18, 2019, in New Orleans, Louisiana.
Site Logo
March 18th 2019

Relationship Between Heart Failure and Diabetes Seen Throughout ACC Sessions

Mary Caffrey
More than a decade after an FDA mandate for cardiovascular outcomes trials, cardiologists say insights gained on how 2 new drug classes affect heart failure in diabetes should be used to prevent complications. Several sessions at the 68th Scientific Session of the American College of Cardiology addressed this topic.
Site Logo
March 17th 2019

Debate Over 30-Day Readmission Metric Dominates Quality Session

Mary Caffrey
A session at the 68th American College of Cardiology Scientific Session continues the ongoing debate whether a CMS reimbursement model has contributed to rising mortality in patients with heart failure.
Site Logo
March 16th 2019

Giant Study Suggests Apple Watch Accurately Catches Atrial Fibrillation

Mary Caffrey
The 68th American College of Cardiology Scientific Session and Exposition opens with a study that suggests the Apple Watch can detect atrial fibrillation with a reasonable degree of accuracy, giving people an opportunity to get in touch with their doctor before a serious event like a stroke.
From the Apple Watch to Heart Failure at Annual Cardiologists' Meeting
March 16th 2019

From the Apple Watch to Heart Failure at Annual Cardiologists' Meeting

Mary Caffrey
In recent years, the big news on the first day of the American College of Cardiology (ACC) Scientific Session and Exposition has involved a therapy—usually an expensive cholesterol drug with a name almost no one could pronounce: proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. This year, it's tech, and an easy-to-pronounce name: Apple.
<1
...
12131415161718192021>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo